Arrowhead Pharmaceuticals and Amgen are developing RNAi-based therapies for dyslipidemias.

1 report, 0 independent Updated Jul 8

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

Arrowhead Pharmaceuticals Amgen

Keep exploring

Part of

Several major pharmaceutical companies, including Pfizer, Amgen, Sanofi, and AstraZeneca, are leading the market for dyslipidemia treatments. All 1 developments

The entities involved

Arrowhead Pharmaceuticals
biopharmaceutical company

Nothing else this week.
Amgen
American multinational biopharmaceutical company
- Amgen, City of Hope, and the California Community Foundation are involved in a life sciences and bioscience economic summit held in Downtown Los Angeles.Mon 12:08
- Geode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Mon 02:05

Coverage

Newest first; wire copies grouped

Jul 8Unknown outlet